FDA TEMPO Pilot Skips AI Approval

A patient shows you an app the FDA hasn't approved

A patient on your ward is using an app to manage his blood pressure medication. He tells you it's "FDA approved." You check. It isn't. Not in the way he means.

What he's using is one of four products in a new FDA pilot called TEMPO, short for Technology-Enabled Meaningful Patient Outcomes. Under TEMPO, the agency is letting select digital health devices reach patients before they clear the FDA's normal premarket review. The tradeoff: the companies collect real-world data while doctors and patients use the product live.

This is not a hypothetical for much longer. It is happening now, and the category it opens up, AI tools on the market without full authorization, is worth understanding before it shows up in your clinic.

What TEMPO actually is

The FDA announced TEMPO in the Federal Register on December 8, 2025, tied to the CMS Innovation Center's ACCESS model, a Medicare experiment in paying for technology that helps beneficiaries manage chronic disease. The agency opened it to statements of interest starting January 2, 2026.

Four companies have since been accepted:

• Dexcom, the first participant, announced July 22, 2026, for its Glucose Health Program, aimed at prediabetes and type 2 diabetes screening.
• Cadence Solutions, whose HypertensionOS tool helps clinicians manage and adjust blood pressure medication for adults with Stage 2 hypertension.
• Limbic, a London-based company whose "Unpacked" service delivers AI-voice cognitive behavioral therapy for anxiety and depression, overseen by a clinician, added August 24, 2026.
• SonderMind, added the same day, offering a smartphone app for anxiety and depression as an adjunct to therapy or medication.

For all four, the FDA is exercising what it calls "enforcement discretion." In plain terms: the agency is choosing not to enforce premarket authorization and investigational device requirements for these specific products, for their intended use inside the ACCESS model, while it watches how they perform.

Why "pilot" is not "approved"

This distinction matters at the bedside. A device cleared through the FDA's normal pathway has been reviewed against a defined evidence bar before anyone touched a patient with it. A device in TEMPO has not. It reached the patient first, and the evidence is being built alongside that use, not before it.

Both companies flagged real limits. Limbic's service is restricted to English speakers with telephone access. SonderMind's app is contraindicated for suicidality, manic episodes, psychosis, and PTSD. These are not small print. They are the actual boundary of what the tool has been allowed to touch, and a doctor who doesn't know they exist can't screen for them.

None of this means TEMPO is a bad idea. Chronic disease management is exactly the kind of problem that benefits from faster, real-world iteration, and Limbic's CEO Ross Harper has said plainly that the goal is to help close a shortage of mental health professionals, a real and pressing gap. The FDA is also not hiding the ball: enforcement discretion is public, documented, and scoped to a specific Medicare payment model, not a blanket exemption.

But it does mean the label "FDA" on a health app is no longer a single, uniform signal. Some products carry it after review. Others carry it while under review, live, on your patients, with contraindications a rushed intake might miss.

What this means on rounds

The practical task this creates for any doctor using AI-adjacent tools, or watching patients bring them in, is a habit: ask which kind of "FDA" you're looking at. Cleared, or piloted. Reviewed, or being reviewed in real time. That's a five-second question with a real answer, and it's the same instinct we push for inside Medows: don't take an AI output on faith, trace it back to what actually backs it up.

TEMPO is worth watching past this one cohort. If the pilot works, expect more generative AI and behavioral health tools to follow this path, reaching patients before the paperwork catches up. The doctors treating those patients should know the difference.

Sources

• FDA: Participants Selected for TEMPO for Digital Health Devices Pilot
• Federal Register: Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot
• MedTech Dive: FDA adds two behavioral health firms to TEMPO pilot
• STAT News: FDA pilot offers generative AI medical devices a path to patients before they are authorized